IL31 and Pruritus: Thus, it is conceivable that FK506 did not target the IL-31 pathway, resulting in weak therapeutic effects on pruritus, which is in line with previous study which showed that IL-31-induced scratching behavior is not inhibited by treatment with FK506 [42].